Johnson & Johnson will invest more than $1 billion in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further expanding its U.S. manufacturing capacity as it advances its portfolio and pipeline of transformational medicines.

“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, Chairman and CEO of Johnson & Johnson. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”

In building this facility, Johnson & Johnson continues to invest in manufacturing processes and training to develop a workforce skilled in advanced technologies that are shaping the future of medicine. It will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.

This investment further strengthens the Company’s longstanding economic impact across Pennsylvania, which totals approximately $10 billion annually. With ten facilities encompassing more than 2 million square feet dedicated to manufacturing, research, distribution, and office operations, Johnson & Johnson maintains one of the most significant, statewide footprints in the healthcare industry.

The announcement is part of the Company’s previously announced $55 billion U.S. investment in manufacturing, research and development, and technology through early 2029.

Other Investments in Pennsylvania

Earlier this year, Eli Lilly and Company chose the Lehigh Valley in Pennsylvania for its next manufacturing site.